A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2016-03-16
Target enrollment:
Participant gender:
Summary
This is a 2-phase study during which patients with relapsed or refractory multiple myeloma
(MM) or plasma cell leukemia (PCL), who have already received at least two previous
treatments, will receive investigational study drug ARRY-520.
The study has 3 parts. In the first part of the study, Phase 1, patients will receive
increasing doses of study drug, with or without granulocyte-colony stimulating factor (G-CSF)
support, in order to achieve the highest dose possible that will not cause unacceptable side
effects. Approximately 30 patients from the US will be enrolled in Part 1 (Active, not
recruiting).
In the second part of the study, Phase 2, patients will receive the best dose of study drug
determined from the first part of the study and will be followed to evaluate what side
effects the study drug causes and what effectiveness it has, if any, in treating the cancer.
Approximately 30 patients from the US will be enrolled in Part 2 (Active, not recruiting).
In the third part of the study, Phase 2 with Dexamethasone, patients will receive the best
dose of the study drug determined from the first part of the study, in combination with
dexamethasone, and will be followed to evaluate what side effects the combination causes and
what effectiveness the combination has, if any, in treating the cancer. Approximately 50
patients from the US will be enrolled in Part 3 (Active, not recruiting).